Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
71 hedge funds and large institutions have $369M invested in Five Prime Therapeutics, Inc. in 2014 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 26 increasing their positions, 15 reducing their positions, and 8 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
157% more capital invested
Capital invested by funds: $144M → $369M (+$226M)
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
73% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 15
13% more funds holding
Funds holding: 63 → 71 (+8)
Top Buyers
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$12.6M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$10.9M |
| 3 |
Goldman Sachs
New York
|
-$7.98M |
| 4 |
QF
QVT Financial
New York
|
-$2.54M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$540K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
76
Prelude Capital Management
New York
| – | -$36K | -3,100 | Closed |
|
|
CCMH
77
Cornerstone Capital Management Holdings
New York
| – | -$35K | -3,000 | Closed |
|
78
BNP Paribas Financial Markets
Paris,
France
| – | -$12.5K | -1,066 | Closed |
|
FPRX Hedge Fund Activity: Q4 2014 in Review
71 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q4 2014, worth a combined $369M — up 157% from $144M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new FPRX positions and 8 closed out — a net gain of 10 holders — while 26 added to existing stakes and 15 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $9.77M. The largest seller was OrbiMed, exiting entirely with an estimated $12.6M sold.
- 71 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q4 2014, up from 63 in Q3 2014.
- Funds reported $369M of Five Prime Therapeutics, Inc. stock for Q4 2014, up 157% quarter-over-quarter.
- 18 funds opened new Five Prime Therapeutics, Inc. positions in Q4 2014 and 8 closed out, a net change of +10 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q4 2014 was Point72 Asset Management, an estimated $9.77M added.
- The largest Five Prime Therapeutics, Inc. seller in Q4 2014 was OrbiMed, an estimated $12.6M sold.
Based on aggregated 13F filings for Q4 2014.